Skip to main content
logo
Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
435.62
+3.62 (0.84%)
At close: Mar 2, 2026, 4:00 PM EST
433.00
-2.62 (-0.60%)
Pre-market: Mar 3, 2026, 9:19 AM EST

Madrigal Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
958.4180.13---
Revenue Growth (YoY)
432.05%----
Cost of Revenue
56.156.23---
Gross Profit
902.26173.9---
Selling, General & Admin
813.83435.06108.1548.1337.32
Research & Development
388.53236.72272.35245.44205.16
Operating Expenses
1,202671.78380.5293.57242.48
Operating Income
-300.1-497.88-380.5-293.57-242.48
Interest Expense
-22.31-14.67-12.71-3.96-
Interest & Investment Income
37.3646.6519.582.190.36
Other Non Operating Income (Expenses)
-0.46---0.27
EBT Excluding Unusual Items
-285.51-465.89-373.63-295.35-241.85
Other Unusual Items
-2.78----
Pretax Income
-288.28-465.89-373.63-295.35-241.85
Net Income
-288.28-465.89-373.63-295.35-241.85
Net Income to Common
-288.28-465.89-373.63-295.35-241.85
Shares Outstanding (Basic)
2221191717
Shares Outstanding (Diluted)
2221191717
Shares Change (YoY)
5.46%13.83%9.05%3.64%7.05%
EPS (Basic)
-12.85-21.90-19.99-17.23-14.63
EPS (Diluted)
-12.85-21.90-19.99-17.23-14.63
Free Cash Flow
-190.02-457.03-325.71-225.07-184.13
Free Cash Flow Per Share
-8.47-21.48-17.43-13.13-11.13
Gross Margin
94.14%96.54%---
Operating Margin
-31.31%-276.39%---
Profit Margin
-30.08%-258.64%---
Free Cash Flow Margin
-19.83%-253.72%---
EBITDA
-298.59-496.78-379.97-293.1-242.08
EBITDA Margin
-31.16%-275.78%---
D&A For EBITDA
1.511.10.530.470.41
EBIT
-300.1-497.88-380.5-293.57-242.48
EBIT Margin
-31.31%-276.39%---
Advertising Expenses
145.152.7---
Updated Feb 19, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q